Search clinical trials for: Fruquintinib，Sintilimab，Pemetrexed，Carboplatin

Total 533 results

The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Wuhan Union Hospital, China

Not yet recruiting

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Stomach Neoplasms

China
RenJi Hospital

Active, not recruiting

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

Stomach Neoplasms

China
Chinese PLA General Hospital

Unknown

Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

Metastasis Colorectal Cancer

China
Hutchmed

Recruiting

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Advanced Solid Tumor

China
AIPING ZHOU

Unknown

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Colorectal Cancer

China
Henan Cancer Hospital

Recruiting

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Metastatic Gastroesophageal Junction Adenocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Henan Cancer Hospital

Recruiting

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Gastric Cancer

China
The First Affiliated Hospital of Xiamen University

Recruiting

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Colorectal Neoplasms

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Metastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung Cancer

China
Wuhan Union Hospital, China
Huazhong University of Science and Technology

Recruiting

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Zhejiang Cancer Hospital

Recruiting

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Xiaofeng Chen

Recruiting

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Colorectal Neoplasms Malignant

China
Avistone Biotechnology Co., Ltd.

Not yet recruiting

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Non-Small-Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

FOLFOX Chemotherapy Plus Fruquintinib and Sintilimab After First-line Treatment in Unresectable Hepatocellular Carcinoma (FOLFOX)

Hepatocellular Carcinoma | Immunotherapy | Second-line Treatment | Anti-angiogenic Therapy | FOLFOX Systemic Chemotherapy
Second Affiliated Hospital of Nanchang University

Not yet recruiting

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

Gastric Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd

Not yet recruiting

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Non-squamous Non-small Cell Lung Cancer

China
Shanghai Jiao Tong University School of Medicine
CSPC Ouyi Pharmaceutical Co., Ltd.; Innovent Biologics, Inc.

Not yet recruiting

Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer (NeoSTEP)

Triple-negative Breast Cancer
University Hospital Muenster
Eli Lilly and Company; Bayer

Terminated

Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib (PECASO)

Carcinoma, Non-Small-Cell Lung

Germany
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

Oropharyngeal Squamous Cell Carcinoma | Oral Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital

Not yet recruiting

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Metastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRC

China
Eli Lilly and Company

Completed

Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cancer

Germany, Argentina, Canada, Poland, Sweden
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Non-squamous Non-small-cell Lung Cancer

China
Xencor, Inc.

Recruiting

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

Nonsquamous Non-small Cell Lung Cancer

United States
BeiGene

Completed

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC

Non-Small Cell Lung Cancer

China
IO Biotech
Merck Sharp & Dohme LLC

Completed

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

NSCLC

United Kingdom, Germany, Netherlands, Spain
Innate Pharma

Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Non Small Cell Lung Cancer

France, United States, Greece, Hungary, Poland
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
The First Affiliated Hospital with Nanjing Medical...

Unknown

Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.

Non-squamous Non-small-cell Lung Cancer
AstraZeneca

Active, not recruiting

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)

Non Small Cell Lung Cancer NSCLC

Poland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
Second Affiliated Hospital, School of Medicine,...

Active, not recruiting

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） (neoSCORE)

Non-small Cell Lung Cancer

China
Pfizer

Completed

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

NSCLC (Non-small Cell Lung Cancer)

Hong Kong, China, Taiwan, Malaysia, Thailand
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma
Hutchison Medipharma Limited

Recruiting

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Advanced Renal Cell Carcinoma

China
Dizal Pharmaceuticals

Recruiting

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Non-small Cell Lung Cancer

China, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Poland, Spain, Turkey
Fudan University

Unknown

A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers

Non-small Cell Lung Cancer

China
Gruppo Oncologico Italiano di Ricerca Clinica

Unknown

Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

Advanced Non-Small Cell Lung Cancer

Italy
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
AstraZeneca

Active, not recruiting

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2)

Non-Small Cell Lung Cancer

United States, Canada, Thailand, Vietnam, France, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, Russian Federation, China, Taiwan, United Kingdom, Czechia, Chile, Australia, Argentina, Slovakia, South Africa
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
Zhejiang Cancer Hospital

Unknown

A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801) (NSCLC)

Non-Small Cell Lung Cancer

China
Eli Lilly and Company

Completed

Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients

Non Small Cell Lung Cancer

France
Sidney Kimmel Cancer Center at Thomas Jefferson...
Eli Lilly and Company

Completed

Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer

Inoperable Non Small Cell Lung Cancer

United States
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer (CCICC-002b)

Non-small Cell Lung Cancer Metastatic | First-line Treatment

China
Sun Yat-sen University

Recruiting

Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC (NIBCUN)

Lung Cancer Stage III

China
Shandong Cancer Hospital and Institute

Recruiting

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unresectable Stage III NSCLC

China
Henan Cancer Hospital

Unknown

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Lung Adenocarcinoma

China

3

Subscribe